NFATC2

Overview

NFATC2 (nuclear factor of activated T-cells 2) encodes a transcription factor in the NFAT family. In oncology, NFATC2 is recognized as a fusion partner for EWSR1 in a rare subclass of undifferentiated small round cell sarcomas (EWSR1::NFATC2), classified under the WHO 2020 category of “round cell sarcoma with EWSR1-non-ETS fusions.”

Alterations observed in the corpus

  • Discussed as a characterised EWSR1-non-ETS fusion partner in the WHO 2020 “round cell sarcoma with EWSR1-non-ETS fusions” category, alongside EWSR1::BEND2, EWSR1::PATZ1, and EWSR1::POU2AF3; the case in question described an EWSR1::BEND2 fusion, placing NFATC2 in differential context PMID:28199314.

Cancer types (linked)

  • Undifferentiated small round cell sarcoma (SARC): EWSR1::NFATC2 fusions define a WHO-recognized sarcoma subtype distinct from classical Ewing sarcoma PMID:28199314.

Co-occurrence and mutual exclusivity

  • EWSR1::NFATC2 is an EWSR1-non-ETS fusion, mutually exclusive with canonical EWSR1::FLI1 Ewing sarcoma fusions PMID:28199314.

Therapeutic relevance

  • No specific targeted therapy reported for EWSR1::NFATC2 fusions; Ewing-sarcoma-like chemotherapy protocols (e.g., ISG/SSG IV) are used in the absence of dedicated trials PMID:28199314.

Open questions

  • WHO classification evolution for EWSR1-non-ETS fusion sarcomas (BEND2, NFATC2, PATZ1, POU2AF3) — whether site/morphology should split or merge these entities remains unresolved PMID:28199314.

Sources

This page was processed by crosslinker on 2026-05-14.